A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection
Latest Information Update: 22 Sep 2021
At a glance
- Drugs Caficrestat (Primary)
- Indications Cardiovascular disorders; COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 01 Sep 2021 Number of treatment arms has been increased from 2 to 3 by the addition of control match group 1 arm and replacing existing arms of hospitalized patients and intervention patients with Interventional Patients: AT-001 and Control Match Group 2 arms. Primary end-points and the time-frame has been changed.
- 23 Feb 2021 Status changed from recruiting to completed.
- 30 Apr 2020 New trial record